The Phase III ENLIVEN study, published in The Lancet in June 2019, looked at the role of pexidartinib in the treatment of people with tenosynovial giant cell tumor (TGCT). The results of this trial led to it’s US FDA in August 2019 for the treatment of adults with symptomatic TGCT associated with severe morbidity or functional limitations and not amenable to improvement with surgery.
As the first approved treatment for TGCT, understanding the findings from the ENLIVEN study are therefore important to patients, their carers and other non-specialist readers. Recognising this need, the authors of the original study sought to develop a plain language summary of the publication, with the aim of publishing the article in a peer-reviewed journal to ensure it is discoverable and citable.
The PLSP entitled ‘ENLIVEN study: Pexidartinib for tenosynovial giant cell tumor (TGCT)’, authored by Dr William Tap, was published in Future Oncology in August 2020 and provides a lay language summary of the ENLIVEN study, enhanced with graphics and images.
The first of it’s kind published in a peer-reviewed journal, we hope this article will encourage others to consider to publishing plain language summaries to help helping lay audiences understand the results of clinical studies and medical research.
Read the article in full here.
The original article, entitled ‘‘Pexidartinib Versus Placebo for Advanced Tenosynovial Giant Cell Tumour (ENLIVEN): A Randomised Phase 3 Trial’ published in The Lancet, can be found here.